scholarly journals Efficacy and Predictors of Survival in Patients with Solitary Hepatocellular Carcinoma Larger than 5 cm undergoing Transarterial Chemoembolization

2021 ◽  
Author(s):  
Ke‐Bin Chang ◽  
Chen‐Ta Chi ◽  
Rheun‐Chuan Lee ◽  
Ming‐Chih Hou ◽  
Yi‐Hsiang Huang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Solitary Hepatocellular Carcinoma

Efficacy of Radiofrequency Ablation versus Transarterial Chemoembolization for Patients with Solitary Hepatocellular Carcinoma ≤3 cm

2019 ◽  
Vol 85 (2) ◽  
pp. 150-155
Author(s):  
Allison N. Martin ◽  
Luke R. Wilkins ◽  
Deepanjana Das ◽  
Lily E. Johnston ◽  
Todd W. Bauer ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Transarterial Chemoembolization ◽  
Small Hepatocellular Carcinoma ◽  
Recurrence Free Survival ◽  
Survival Functions ◽  
Rank Tests ◽  
Free Survival ◽  
Kaplan Meier ◽  
Solitary Hepatocellular Carcinoma

Optimal treatment for small hepatocellular carcinoma (HCC) ≤ 3 cm remains controversial. Ablation and chemoembolization are considered for nonoperative candidates. This study compares survival among patients with solitary HCC ≤ 3 cm treated with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Patients diagnosed with HCC ≤ 3 cm between 2005 and 2014 were included. Kaplan-Meier survival functions with log-rank tests were used to estimate recurrence-free survival and overall survival (OS) survival. Among 161 patients with solitary HCC ≤ 3 cm, 145 patients with mean age of 65.2 years (69.2) and 95 per cent prevalence of cirrhosis had operative treatment or TACE, and/or RFA. From this cohort, 27 (19%) patients had TACE, 27 (19%) patients had RFA, and 15 (10%) patients had TACE/RFA. The patients treated with definitive TACE, RFA, or TACE/RFA had a similar 1-year recurrence-free survival (23% vs 27% vs 36%, respectively, P = 0.445) and similar 5-year OS (21% vs 24% vs 33%, respectively, P = 0.287). Thirty-five (24%) patients were bridged to transplantation with TACE and/or RFA. The 5-year OS was significantly improved in patients bridged to transplantation (P < 0.001). Survival does not differ between patients with solitary HCC ≤ 3 cm treated with TACE or RFA. Patients who were bridged to transplantation had significantly greater OS compared with patients who were not transplanted.

Sign in / Sign up

Export Citation Format

Share Document